| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5712298 | ASTRAZENECA | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
Jan, 2020
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9468598 | ASTRAZENECA | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
Feb, 2023
(1 year, 1 month ago) | |
| US8431154 | ASTRAZENECA | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient |
Feb, 2023
(1 year, 1 month ago) | |
| US8536206 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(a month ago) | |
| US8618142 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(a month ago) | |
| US8604064 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(a month ago) | |
Daliresp is owned by Astrazeneca.
Daliresp contains Roflumilast.
Daliresp has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Daliresp are:
- US9468598
- US8431154
- US8536206
- US8618142
- US8604064
- US5712298
Daliresp was authorised for market use on 23 January, 2018.
Daliresp is available in tablet;oral dosage forms.
Daliresp can be used as treatment to reduce the risk of copd exacerbations in patients with severe copd associated with chronic bronchitis and a history of exacerbations.
Drug patent challenges can be filed against Daliresp from 28 February, 2015.
The generics of Daliresp are possible to be released after 08 March, 2024.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-208) | Aug 31, 2020 |
| New Strength(NS) | Jan 23, 2021 |
| New Dosing Schedule(D-171) | Jan 23, 2021 |
| New Chemical Entity Exclusivity(NCE) | Feb 28, 2016 |
Drugs and Companies using ROFLUMILAST ingredient
NCE-1 date: 28 February, 2015
Market Authorisation Date: 23 January, 2018
Treatment: Treatment to reduce the risk of copd exacerbations in patients with severe copd associated with chronic bronchitis and a history of exacerbations
Dosage: TABLET;ORAL
DALIRESP family patents
